Cancer cell membrane-coated mesoporous silica loaded with superparamagnetic ferroferric oxide and Paclitaxel for the combination of Chemo/Magnetocaloric therapy on MDA-MB-231 cells

Sci Rep. 2019 Oct 9;9(1):14475. doi: 10.1038/s41598-019-51029-8.

Abstract

To effectively inhibit the growth of breast cancer cells (MDA-MB-231 cells) by the combination method of chemotherapy and magnetic hyperthermia, we fabricated a biomimetic drug delivery (CSiFePNs) system composed of mesoporous silica nanoparticles (MSNs) containing superparamagnetic ferroferric oxide and Paclitaxel (PTX) coated with MDA-MB-231 cell membranes (CMs). In the in vitro cytotoxicity tests, the MDA-MB-231 cells incubated with CSiFePNs obtained IC50 value of 0.8 μgL-1, 3.5-fold higher than that of SiFePNs. The combination method of chemotherapy and magnetic hyperthermia can effectively inhibit the growth of MDA-MB-231 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Phytogenic / administration & dosage*
  • Biological Transport, Active
  • Biomimetic Materials / administration & dosage
  • Biomimetic Materials / chemistry
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Cell Line, Tumor
  • Cell Membrane / metabolism
  • Cell Proliferation / drug effects
  • Combined Modality Therapy
  • Drug Delivery Systems
  • Female
  • Humans
  • Hyperthermia, Induced / methods
  • Magnetite Nanoparticles / administration & dosage*
  • Magnetite Nanoparticles / chemistry
  • Magnetite Nanoparticles / ultrastructure
  • Paclitaxel / administration & dosage*
  • Silicon Dioxide / chemistry

Substances

  • Antineoplastic Agents, Phytogenic
  • Magnetite Nanoparticles
  • Silicon Dioxide
  • Paclitaxel